Xinhua Pharmaceutical (000756): API price increases, performance increases, performance is flexible, specialty formulation CMO lays the foundation for long-term growth
Xinhua Pharmaceutical (000756) Dynamic Analysis: The sharp rise in the volume and price of ibuprofen brings performance elasticity, the international strategy is progressing in an orderly manner, and valuations are expected to increase
Xinhua Pharmaceutical (000756): A Year of Accelerated Transformation of Leading Antipyretic and Analgesic APIs to CMO
Xinhua Pharmaceutical (000756): Performance meets expectations, and consistent evaluations have been harvested one after another
Xinhua Pharmaceutical (000756) in-depth Research report: defense value highlights steadfast and enterprising in the future
Xinhua Pharmaceutical (000756): Revenue continues to grow, gross margin increases further
Xinhua Pharmaceutical (000756): the performance is in line with the expected volume and price of raw materials.
Xinhua Pharmaceutical (000756) Review: The publication of draft stock options bundles benefits the long term
Xinhua Pharmaceutical (000756) report comments: performance is slightly lower than expected consistency evaluation is progressing smoothly
Xinhua Pharmaceutical (000756) Annual report comments: performance growth is in line with expectations and wait for the change to continue to deepen
Xinhua Pharmaceutical (000756) Annual Report Review: Q4 Performance Growth Rate Recovers, Consistency Evaluation Ushers in Harvest Period
Xinhua Pharmaceutical (000756): High performance growth and investment value highlighted
Xinhua Pharmaceutical (000756) Commentary on important issues: 2017 performance was slightly lower than expected endogenous reserves lay the foundation for subsequent growth
Xinhua Pharmaceutical (000756) Incident Review: API Sentiment Boosts Performance High Growth
Event: The company released its 2017 performance forecast: Net profit attributable to listed companies in 2017 was 184 million yuan to 244 million yuan, an increase of 50%-100% over the previous year, in line with previous expectations. Key investment poin
Xinhua Pharmaceutical (000756) Dynamic Tracking Report: Q4 Performance Recovers High Growth, Formulation Consistency Evaluation Value Expectations
Xinhua Pharmaceutical (000756) In-depth Study: Integrated Generic Pharmaceutical Companies Benefit from Supply-Side Industry Reforms
Xinhua Pharmaceutical (000756) Investment Value Analysis Report: Multi-dimensional Industrial Value Revaluation of Formulations and APIs Raising Sharply
Xinhua Pharmaceutical (000756) Third Quarterly Report Review: Continued Revenue Growth, Increased Land Yield, Increased Performance
Xinhua Pharmaceutical (000756) Review of the Third Quarterly Report: The price of APIs continues to rise, and the winning bid prices of low-priced drugs have increased dramatically
No Data